What targeted cancer treatment planning actually involves
Targeted cancer treatment is not one treatment. It is a group of medicines that act on specific molecular features of a cancer. The National Cancer Institute explains that these treatments interfere with particular molecules involved in cancer growth and spread, which is why biomarker testing often matters before a clinician can assess whether a targeted option is relevant.
For an overseas patient, that means the first useful step is not choosing a hospital or booking flights. It is clarifying what your current pathology and molecular reports already show, what your treating team abroad has concluded from them, and what specific question you want a Chinese specialist to address. A records-based review can help identify whether there is a genuine clinical question to pursue, but it does not confirm that a particular medicine is available, suitable or funded in China.
The decision you are actually making is narrower than 'should I go to China for treatment'. It is: is there a specific targeted therapy question that a Chinese hospital can help answer, and can that be done without disrupting the care you already have?
Decisions to make before any booking
Before you commit to travel, work through four decisions in order. Each one changes whether the next step makes sense.
First, is there an unresolved clinical question? If your current team has already tested the relevant biomarkers and has a clear plan, a second opinion may add little. If testing is incomplete, or if results suggest options that are not available or not funded where you live, a records-based review may be worth requesting.
Second, what does your current treating team think? Ask them directly whether a short period of assessment or treatment in China is medically reasonable, what they would need to see afterwards, and whether any interruption to your current regimen is acceptable. Do not stop or change prescribed treatment on your own.
Third, what records exist and in what language? Pathology reports, molecular or genomic test results, imaging, treatment history and current medication lists are the core documents a receiving clinician would need to assess your case. If reports are in a language the Chinese hospital cannot read, ask whether certified translation is required and who arranges it.
Fourth, what would you do if the answer is 'no'? A records review may conclude that no targeted option is currently suitable, that more testing is needed, or that your existing plan is already appropriate. Decide in advance how you would handle that outcome, including whether you would still travel for a consultation.
Records to prepare and questions to ask the Chinese team
You do not need to send a complete medical archive at first contact. A short summary of the diagnosis, the main question and the key reports is enough to begin. If the case looks suitable for further review, the hospital or coordination team will tell you what else is needed.
When you do share records, the most useful set for a targeted therapy question typically includes: the original pathology report, any molecular or genomic testing reports with the specific variants reported, recent imaging and staging information, a chronological treatment history with dates and responses, current medicines and doses, and recent blood tests. Ask the receiving clinician which of these they actually require rather than sending everything.
Prepare a short list of questions whose answers would change your next step. For example: Does the hospital have the specific medicine or class of medicine you are asking about? Is it available for your indication, or only within a clinical trial? What additional testing would the hospital want before deciding? How would treatment be monitored, and what would be expected of your team abroad between visits? What is the hospital's written estimate of the main costs, and what does that estimate include?
Ask for answers in writing where possible. Verbal reassurance about availability or cost is difficult to rely on when you are planning international travel.
- Pathology report and any molecular or genomic test results
- Recent imaging and current staging information
- Chronological treatment history with dates and responses
- Current medicines, doses and recent blood tests
- A short written summary of your main question
Trip feasibility: what to confirm before flights
Trip feasibility for targeted cancer treatment is not a single yes-or-no answer. It depends on whether the hospital accepts your case, what stage of assessment or treatment you would be travelling for, how long the hospital expects you to stay, and what your current clinical condition allows.
Ask the hospital or coordination team to confirm in writing: whether an appointment has been offered or is still provisional; what the visit is for (consultation, additional testing, treatment start, or review); what the hospital's own estimate of the stay is; and what would need to be true for the trip to proceed. Treat any timeline you are given as the hospital's estimate for your case, not a general rule.
Do not assume that a first visit will lead directly to treatment. A consultation may result in a recommendation for further testing, a different approach, or a conclusion that your existing plan should continue. Plan the trip so that a 'no treatment this visit' outcome is manageable.
If you are currently receiving treatment abroad, ask your current team what they need to know before you travel, whether any gap in treatment is acceptable, and what monitoring or bridging arrangements they would recommend. Those are clinical decisions for your treating clinicians, not for a coordination service.
Practical support during a China visit
Practical support for a targeted therapy visit is different from support for a short procedure. You may need help with hospital registration, interpretation during consultations, understanding consent discussions, and coordinating between departments if testing and treatment are handled by different teams.
Before any sedation, procedure or new treatment, make sure you understand what is being proposed, what the alternatives are, and what the risks and restrictions are. Ask for interpretation if the discussion is not in a language you are confident using. Consent discussions should happen before, not after, any sedating medication.
If you need help with hospital navigation, interpretation or local arrangements, these can be discussed as separately agreed coordination services. They are not clinical care, and they do not replace the treating team's judgement about your treatment.
Keep your team abroad informed. Ask the Chinese hospital what documentation they can provide after the visit — consultation notes, test results, a treatment summary — and how long that may take. Then confirm with your own team what format they need.
Contingencies and the next step
Plan for three outcomes. One: the hospital confirms a relevant targeted option and offers an appointment. Two: the hospital needs more testing or information before deciding. Three: the review concludes that no change to your current plan is warranted, or that the option you asked about is not available for your case.
Each outcome has a different next step, so decide in advance how you would respond to each. For outcome two, ask what specific tests or documents are missing and who can obtain them. For outcome three, ask for the reasoning in writing so your current team can consider it.
If you want to explore whether a records-based review is worthwhile, you can start with a free initial enquiry. Our team checks the available diagnosis, records and your main question, identifies missing information and suggests a relevant next step. This is not a diagnosis or a promise of acceptance, and it does not require buying a proxy consultation. The hospital decides suitability.
A brief summary is enough to begin. Share your diagnosis, the specific targeted therapy question and the key reports; the team will tell you what else is needed if the case moves forward.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.